Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

New cholesterol lowering drugs on the horizon

New cholesterol lowering drugs on the horizon

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

New cERD method can detect RNAi activity in biological fluids

New cERD method can detect RNAi activity in biological fluids

First study to examine how changes in fitness and fatness affect heart health

First study to examine how changes in fitness and fatness affect heart health

FDA grants Mylan tentative approval for Atorvastatin Calcium ANDA

FDA grants Mylan tentative approval for Atorvastatin Calcium ANDA

Alnylam receives U.S. patent allowance for LNP platform

Alnylam receives U.S. patent allowance for LNP platform

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

NYU Langone cardiovascular experts present new research findings at AHA 2011

NYU Langone cardiovascular experts present new research findings at AHA 2011

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Logistic regression models identify risk factors for open angle glaucoma

Logistic regression models identify risk factors for open angle glaucoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.